流感疫苗市场规模、份额、成长分析（按类型、适应症、技术、给药途径、年龄层、分销管道和地区）—2025 年至 2032 年产业预测

2023 年全球流感疫苗市场价值为 79 亿美元，预计将从 2024 年的 84.4 亿美元成长到 2032 年的 142.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.8%。

流感病毒仍然是持续的健康威胁，造成局部流行病和大量死亡。仅在 2019-20 年流感季节，美国疾病管制与预防中心就报告了超过 1,300 万例流感病例。由于病毒不断进化，每年调整疫苗株以达到最佳效果至关重要。随着流感疫情持续上升，疫苗需求的成长预计将推动市场销售。目前，多种季节性流感疫苗已获得世界卫生组织（WHO）和美国疾病管制与预防中心（CDC）的核准，世界各国政府都优先接种疫苗，以在流感季节最大限度地保护本国公民。製药业在疫苗开发方面面临持续的挑战，进一步增加了市场对创新有效流感疫苗的需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术分析

流感疫苗市场规模（按类型及复合年增长率） (2025-2032)

• 市场概览
• 惰性
• 减毒活疫苗

流感疫苗市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概览
• 四价
• 三价

流感疫苗市场规模（依技术及复合年增长率） (2025-2032)

• 市场概览
• 鸡蛋为主
• 基于细胞

流感疫苗市场规模（依给药途径和复合年增长率） (2025-2032)

• 市场概览
• 注射
• 鼻喷剂

流感疫苗市场规模（依年龄层及复合年增长率） (2025-2032)

• 市场概览
• 儿科
• 成人

流感疫苗市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院和药房
• 政府及机构用品
• 其他的

流感疫苗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Sanofi Pasteur（France）
• GlaxoSmithKline plc（GSK）（United Kingdom）
• Seqirus（a CSL Limited Company）（Australia）
• Pfizer Inc.（United States）
• AstraZeneca PLC（United Kingdom）
• Novavax, Inc.（United States）
• Bharat Biotech（India）
• Johnson & Johnson（United States）
• MedImmune, LLC（AstraZeneca）（United States）
• FluGen（United States）
• Emergent BioSolutions（United States）
• Sinovac Biotech Ltd.（China）
• Bio Farma（Indonesia）
• Serum Institute of India Pvt. Ltd.（India）
• Abbott Biologicals BV（Netherlands）
• Adimmune Corporation（Taiwan）
• BIKEN Co., Ltd.（Japan）
• Changchun BCHT Biotechnology Co.（China）

结论和建议

Global Influenza Vaccine Market size was valued at USD 7.9 billion in 2023 and is poised to grow from USD 8.44 billion in 2024 to USD 14.28 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The influenza virus remains a persistent health threat, causing regional epidemics and leading to significant mortality. In the 2019-20 season alone, the Centers for Disease Control and Prevention reported over 13 million flu cases. Due to the virus's evolving nature, annual adjustments to vaccine strains are essential for optimal effectiveness. As influenza outbreaks continue to increase, a growing demand for vaccines is anticipated to drive market sales. Currently, various licensed seasonal influenza vaccines are endorsed by the World Health Organization and CDC to combat the virus, with governments emphasizing vaccination to maximize public protection during flu seasons. The pharmaceutical sector faces ongoing challenges in vaccine development, further heightening the demand for innovative and effective influenza vaccines in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Influenza Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Influenza Vaccine Market Segments Analysis

Global Influenza Vaccine Market is segmented by Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel and region. Based on Type, the market is segmented into Inactivated and Live Attenuated. Based on Indication, the market is segmented into Quadrivalent and Trivalent. Based on Technology, the market is segmented into Egg-based and Cell-based. Based on Route of Administration, the market is segmented into Injection and Nasal Spray. Based on Age Group, the market is segmented into Pediatric and Adult. Based on Distribution Channel, the market is segmented into Hospital & Pharmacies, Government & Institutional Supply and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Influenza Vaccine Market

Government support and enhanced surveillance for influenza vaccinations are pivotal drivers of the global influenza vaccine market. Effective monitoring at both national and international levels is essential to oversee the supply, distribution, and administration of flu vaccines. Organizations like the World Health Organization (WHO) collaborate with various governments to assess demand and implement immunization programs aimed at reducing regional vaccine requirements. For example, in 2021, the Australian government successfully vaccinated around 5 million individuals through its immunization initiatives, with over 20 million doses still available for further distribution. This ongoing commitment underscores the essential role of government intervention in stimulating vaccine uptake.

Restraints in the Global Influenza Vaccine Market

The global influenza vaccine market faces significant restraints primarily due to the lengthy and complex nature of vaccine development, which typically spans 10 to 15 years. This protracted timeline is influenced by several factors, including the intricacies involved in creating vaccines, the need for global clinical trials, and the variations in regulatory requirements across different regions. These regulatory variations can result in considerable delays as countries often have distinct labeling mandates and compressed timelines for clinical trials. The cumulative effect of stringent regulations and extended development periods is expected to hinder the progress of novel influenza vaccine products in the market.

Market Trends of the Global Influenza Vaccine Market

The Global Influenza Vaccine market is experiencing a notable upward trend, propelled by the heightened awareness surrounding immunization following the coronavirus pandemic. As health experts and government health departments amplify their advocacy for flu vaccinations, more individuals are opting for these preventive measures, leading to a surge in vaccination rates in both developing and developed countries. Additionally, the extension and expansion of government programs offering free flu vaccinations have further incentivized uptake. This evolving landscape underscores a growing emphasis on public health initiatives, thereby driving an increase in market demand and fostering opportunities for vaccine manufacturers and healthcare providers alike.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Influenza Vaccine Market Size by Type & CAGR (2025-2032)

• Market Overview
• Inactivated
• Live Attenuated

Global Influenza Vaccine Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Quadrivalent
• Trivalent

Global Influenza Vaccine Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Egg-based
• Cell-based

Global Influenza Vaccine Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Injection
• Nasal Spray

Global Influenza Vaccine Market Size by Age Group & CAGR (2025-2032)

• Market Overview
• Pediatric
• Adult

Global Influenza Vaccine Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital & Pharmacies
• Government & Institutional Supply
• Other

Global Influenza Vaccine Market Size & CAGR (2025-2032)

• North America (Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel)
  • US
  • Canada
• Europe (Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Sanofi Pasteur (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seqirus (a CSL Limited Company) (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MedImmune, LLC (AstraZeneca) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FluGen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinovac Biotech Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Farma (Indonesia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Biologicals B.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adimmune Corporation (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIKEN Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Changchun BCHT Biotechnology Co. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations